The new health and beauty care standouts of 2003

Many treatments for hemophilia A and B are administered via intravenous infusions, so the approval offers a subcutaneous injection for the treatment for patients 12 years and older.

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

The therapy is now the first and only oral on-demand treatment option for the condition.

This approval offers pediatric patients and caregivers the first subcutaneous option that can be administered at home.

Bullous pemphigoid is a rare skin condition that causes large blisters filled with fluids that typically occur near skin creases, such as the upper thighs and armpits.